Study To Determine Safety/Efficacy of Lucentis For Treatment Of Retinal Angiomatous Proliferation Secondary To Age Related Macular Degeneration
Public ClinicalTrials.gov record NCT00395707. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase I Study Of Intravitreal Ranibizumab (Lucentis) For The Treatment Of Stage 1 And 2 Retinal Angiomatous Proliferations
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective of this study is to determine the safety \& efficacy of ranibizumab for the treatment of retinal angiomatous proliferation secondary to age related macular degeneration.
Study identification
- NCT ID
- NCT00395707
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 20 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 50 Years and older
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 31, 2005
- Primary completion
- Mar 31, 2008
- Completion
- Mar 31, 2008
- Last update posted
- Feb 8, 2009
2005 – 2008
United States locations
- U.S. sites
- 2
- U.S. states
- 1
- U.S. cities
- 2
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| National Retina Institute | Chevy Chase | Maryland | 20815 | — |
| National Retina Institute | Towson | Maryland | 21204 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Macular Degeneration trials
Other public records listing Macular Degeneration. Sorted by last update posted; newest first. Not a recommendation.
- NCT07216924: Remapping Text in Sentence and Word Tasks to Aid Reading With Central Vision Loss Not yet recruiting
- NCT07577219: Vision Rehabilitation Training With Multimodal Feedback in Central Vision Loss Recruiting
- NCT04567303: Study of Zifibancimig in Participants With Neovascular Age-related Macular Degeneration Active, not recruiting
- NCT07496567: A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003) Recruiting
- NCT07440225: A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002) Recruiting
- NCT06779773: A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00395707, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 8, 2009 · Synced Sep 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00395707 live on ClinicalTrials.gov.